NeuroSense published its financial results for the quarter ended June 30, 2023 and provided a business update.
Business Updates include –
- Capital Raise of $4.5 Million
- Phase 2b Amyotrophic Lateral Sclerosis (ALS) PARADIGM Trial Completed Patient Enrollment
- Strategic Scientific Agreement with Biogen
- Phase 2 Alzheimer’s Disease (AD) Trial Under Preparation